London-based Tiziana Life Sciences has appointed Dr Robert Evans as its new vice president of clinical sciences.
Dr Evans joins the clinical stage biotechnology company from Glenmark Pharmaceuticals, where he also served as vice president of clinical sciences.
In that role, he was responsible for providing project and clinical leadership across multiple programmes focused on the treatment of oncology, respiratory and dermatology disorders.
Prior to this, Dr Evans held a number of scientific leadership positions while at Amgen, Johnson & Johnson and Regeneron.
James Tripp, chief operating officer at Tiziana Life Sciences, said: “Bob’s extensive background in the clinical development industry… combined with his strong background in immunology and oncology adds tremendous support to our exciting portfolio.
“I am very confident that together with out impressive pipeline and strong team we will continue to drive the company forward to significant future success.”